Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

समान संसाधन

• Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study
  द्वारा: Olmos, David, और अन्य
  प्रकाशित: (2009)
• Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma
  द्वारा: Juergens, Heribert, और अन्य
  प्रकाशित: (2011)
• Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma
  द्वारा: Zhang, Tiehong, और अन्य
  प्रकाशित: (2014)
• Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin
  द्वारा: Karp, Daniel D., और अन्य
  प्रकाशित: (2009)
• Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
  द्वारा: Gualberto, A, और अन्य
  प्रकाशित: (2011)